Press Release

EyeBiotech Limited Announces $130 Million Series A

November 14, 2023

London – November 14, 2023 – Cooley advised EyeBiotech Limited (EyeBio), a privately held, clinical-stage ophthalmology biotechnology company working to deliver a new generation of therapies for eye diseases, on the close of an extension to its Series A financing, bringing the total raised to date to $130 million. Partner Tom Goodman led the Cooley team advising EyeBio.

New investors – Bain Capital Life Sciences, Omega Funds and Vertex Ventures HC – joined the financing round, which included participation from existing investors, SV Health Investors, Jeito Capital, Samsara Biocapital and MRL Ventures Fund. Proceeds from the financing will be used to accelerate EyeBio’s clinical development program and further build out its innovative retina pipeline.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has more than 1,300 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of nearly 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.